GlassScriptPhysician profile
John Taylor Mackay
NPI 1942267844
$951.97
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $159 · 2022: $38.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $154.79 | 2019-2020 | |
| Amgen INC. | $117.65 | 2019-2022 | |
| Novo Nordisk INC | $101.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $79.13 | 2019-2020 | |
| Abbvie INC. | $67.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.83 | 2019 | |
| Pfizer INC. | $51.24 | 2019 | |
| Astellas Pharma US INC | $45.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2019 | |
| Glaxosmithkline, LLC. | $18.45 | 2019 | |
| Lilly USA, LLC | $18.34 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.75 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.86 | 2019 | |
| Endo Pharmaceuticals INC. | $13.17 | 2020 | |
| Allergan, INC. | $11.56 | 2020 | |
| Sanofi Pasteur INC. | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mackay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.